FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]RESEARCHSemaglutide in Alcohol Use Disorder [NCT07949474]RESEARCHEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]NEWS‘Selling and marketing snake oil’: The debate over compounded GLP-1sRESEARCHSemaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]RESEARCHTirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]RESEARCHSemaglutide in Alcohol Use Disorder [NCT07949474]RESEARCHEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]NEWS‘Selling and marketing snake oil’: The debate over compounded GLP-1sRESEARCHSemaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]RESEARCHTirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]

Pour des fins de recherche uniquement. Déclaration complète →

Recherche/Papier
Retour à la bibliothèque de recherche
PubMedReview

A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist.

Min Jee Sun, Jo Seong Jun, Lee Sangyoung, Kim Duk Yeon, Kim Da Hyun, Lee Chae Bin, Bae Soo Kyung
Drug design, development and therapy2025DOI: 10.2147/DDDT.S506957
GLP-1 receptor agoniststirzepatideexenatideliraglutidedulaglutidesemaglutide

Note de qualité

7/10

Citations

0

Sujets

Non-humain

Analyse Peptide Contacts

Study Design

Review papers serve a critical role in synthesizing disparate findings into a coherent narrative. For rapidly evolving fields like peptide therapeutics, reviews help researchers and practitioners identify consensus and controversy.

Our Assessment

Quality Assessment: 7/10 — This is a solidly conducted study with clear methodology and reasonable conclusions. Minor limitations exist (noted below) but don't undermine the core findings. The evidence here is reliable enough to inform both research direction and practical decision-making.

Findings in Context

The results for GLP-1 receptor agonists, tirzepatide, exenatide, liraglutide, dulaglutide, semaglutide are encouraging.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: Strong methodology makes this a valuable addition to the GLP-1 receptor agonists, tirzepatide, exenatide, liraglutide, dulaglutide, semaglutide evidence base. The findings here should inform future clinical trial design.

Trouvailles clés

The review comprehensively examines the pharmacokinetics and drug-drug interactions of approved GLP-1 receptor agonists and a dual GLP-1/GIP receptor agonist, highlighting structural modifications that prolong half-life but may increase adverse event risk. It also notes significant changes in exposure for oral contraceptives and levothyroxine with tirzepatide and semaglutide.

Limites

The review is limited by the lack of clinical data on drug-metabolizing enzyme- and transporter-mediated DDIs, and a need for further investigation into alterations in volume of distribution and clearance due to other mechanisms of action.

Comment interpréter cette recherche

1

Look for the sample size — larger studies produce more reliable results. Single-digit sample sizes warrant caution.

2

Check whether the study was funded by a pharmaceutical company or conducted independently, as funding sources can influence study design and reporting.

3

Reviews are only as good as the studies they include. Check whether the review examined study quality or simply tallied results.

4

Look for discussion of publication bias — studies with negative results are less likely to be published, which can skew review conclusions.

5

Always consult a qualified healthcare provider before making treatment decisions based on research findings. Published research is not a substitute for personalized medical advice.

Analyse Peptide Contacts

Highlighting the latest advancements and considerations for clinicians using GLP-1 receptor agonists and tirzepatide in treating type 2 diabetes and obesity.

GLP-1 receptor agoniststirzepatideexenatideliraglutidedulaglutidesemaglutide

GLP-1 Receptor Agonists: Advancements in Pharmacokinetics and Drug Interactions

Published: May 16, 2026 | Source: Drug design, development and therapy (2025) | Category: GLP-1 receptor agonists, tirzepatide, exenatide, liraglutide, dulaglutide, semaglutide

Overview

A recent comprehensive review published in Drug Design, Development and Therapy provides critical insights into the pharmacokinetics and drug-drug interactions of approved GLP-1 receptor agonists (GLP-1 RAs) and a dual GLP-1/GIP receptor agonist. This study highlights how structural modifications to these peptides extend their half-life but may also increase the risk of adverse events, impacting clinical use in treating type 2 diabetes and obesity.

Study Background

GLP-1 RAs were initially developed to treat type 2 diabetes by mimicking the effects of natural GLP-1. However, native human GLP-1 has a very short half-life (approximately 2 minutes), necessitating structural modifications such as amino acid sequence changes, fatty acid conjugation, and fusion with albumin or Fc regions to enhance their therapeutic utility. The introduction of tirzepatide, which targets both GLP-1 and GIP receptors, further expanded the potential for these peptides in managing obesity.

What the Research Found

The review examines four approved GLP-1 RAs—exenatide, liraglutide, dulaglutide, and semaglutide—and tirzepatide. Key findings include:

  • Pharmacokinetics: Structural modifications have led to minimal metabolism and renal excretion for these peptides, resulting in prolonged half-lives compared to native GLP-1.
  • Drug-Drug Interactions (DDIs): Clinically significant DDIs mediated by drug-metabolizing enzymes or transporters are rare. However, mechanism-of-action-mediated DDIs involving delayed gastric emptying have been noted but generally considered clinically insignificant.
  • Specific Drug Interactions: Significant changes in exposure were observed for oral contraceptives and levothyroxine with the use of tirzepatide and semaglutide, respectively.

What This Means for Peptide Users

Clinicians need to be aware that while structural modifications have greatly improved the efficacy and convenience of GLP-1 RAs by extending their half-lives, they may also introduce new risks. For instance, patients taking oral contraceptives or levothyroxine should be closely monitored when using tirzepatide or semaglutide due to potential changes in drug exposure.

Limitations and Caveats

The review highlights several limitations:

  • Lack of Clinical Data: There is a dearth of clinical data on DDIs mediated by drug-metabolizing enzymes and transporters.
  • Volume of Distribution and Clearance Alterations: Further research is needed to understand how other mechanisms of action, such as changes in fat mass or cytochrome P450 activity, affect the pharmacokinetics of these peptides.

How This Compares to Previous Research

Previous studies have focused on individual GLP-1 RAs but lacked a comprehensive review that includes both pharmacokinetic profiles and DDIs. This study provides a consolidated view, making it easier for clinicians to understand the broader implications of using these therapies.

Our Analysis

PeptideVault's analysis suggests that while this review offers valuable insights into the current state of GLP-1 RAs and tirzepatide, there is still room for more detailed clinical studies on DDIs. The findings underscore the importance of personalized medicine approaches when prescribing these agents to ensure optimal safety and efficacy.

Key Takeaways

  • Structural Modifications: Enhance therapeutic utility but may increase adverse event risk.
  • DDI Monitoring: Clinicians should closely monitor patients using oral contraceptives or levothyroxine with tirzepatide or semaglutide.
  • Further Research Needed: Detailed clinical studies on DDIs and the impact of other mechanisms of action are essential.

Original Source

Citation: Min Jee Sun, Jo Seong Jun, Lee Sangyoung et al. (2025). A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist.. Drug design, development and therapy. DOI: 10.2147/DDDT.S506957

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Note de l'éditeur

Cette analyse a été rédigée par l'équipe de recherche de Peptide Contacts pour rendre les découvertes complexes accessibles à la communauté des peptides. Nous encourageons les lecteurs à vérifier le papier source pour une méthodologie et des données complètes. Pour plus d'informations sur GLP-1 receptor agonists, explorez nos guides de recherche.

Citation

Min Jee Sun, Jo Seong Jun, Lee Sangyoung et al.. (2025). A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist.. Drug design, development and therapy. https://doi.org/10.2147/DDDT.S506957

Voir le texte intégral sur PubMed

Papiers connexes

Explorer davantage

Ce contenu est dérivé d'une recherche peer-reviewed pour des fins éducatives uniquement. Il ne constitue pas un avis médical. Consultez toujours un fournisseur de soins de santé qualifié avant d'utiliser tout traitement basé sur les peptides.